Xencor
XNCRAlgoritmens signaler
- ›Starkt 3m-momentum (+69.4%)
- ›Starkt 6m-momentum (+63.2%)
- ›Starkt 12m-momentum (+154.2%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›Hög volatilitet (69% årlig)
- ›+192% från 52v-botten
- ›Ökad handelsvolym (+28%)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsVanguard Capital Management (XNCR) discloses 3.8M-share, 5.13% stake in Xencor - Stock Titan
2 d sedanVanguard Capital Management (XNCR) discloses 3.8M-share, 5.13% stake in Xencor Stock Titan
Stock TitanXNCR|Xencor Inc|Price:21.470|Chg%:+1.940 - TradingKey
2 d sedanXNCR|Xencor Inc|Price:21.470|Chg%:+1.940 TradingKey
TradingKeyXencor Secures Ultomiris Royalty Settlement Payment - theglobeandmail.com
3 d sedanXencor Secures Ultomiris Royalty Settlement Payment theglobeandmail.com
theglobeandmail.comXencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ) - Seeking Alpha
3 d sedanXencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ) Seeking Alpha
Seeking AlphaXencor (XNCR) Reiterated by Wedbush -- Rating Maintained at Outp - GuruFocus
3 d sedanXencor (XNCR) Reiterated by Wedbush -- Rating Maintained at Outp GuruFocus
GuruFocusXencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
4 d sedanXencor, Inc. (NASDAQ:XNCR) (“Xencor”), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced its agreement wi
XencorBusiness WireXencor (XNCR) Expected to Post Earnings on Wednesday - MarketBeat
4 d sedanXencor (XNCR) Expected to Post Earnings on Wednesday MarketBeat
MarketBeatXencor (XNCR) Updates Its Pipeline, Is The Stock Still Cheap? - simplywall.st
2026-07-22Xencor (XNCR) Updates Its Pipeline, Is The Stock Still Cheap? simplywall.st
simplywall.stXencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock? - Yahoo Finance
2026-07-20Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock? Yahoo Finance
Yahoo FinanceXencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
2026-07-17Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1
XencorBusiness WireXencor Reports First Quarter 2026 Financial Results
2026-05-06Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fi
XencorBusiness WireXencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
2026-05-04Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the Phase
XencorBusiness WireXencor Announces Change to Ultomiris® Royalty Revenue Forecast
2026-03-04Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceutical
XencorBusiness WireXencor Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-25Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fo
XencorBusiness WireXencor to Participate at Upcoming Investor Conferences
2026-02-23Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management wil
XencorBusiness WireXencor Highlights Corporate Priorities and 2026 Pipeline Milestones
2026-01-08Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 20
XencorBusiness Wire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.